Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

New England Journal of Medicine

Volumn 313, Issue 23, 1985, Pages 1485-1492

  Rosenberg, Steven A ^a   Lotze, Michael T ^a   Muul, Linda M ^a   Leitman, Susan ^a   Chang, Alfred E ^a   Ettinghausen, Stephen E ^a   Matory, Yvedt L ^a   Skibber, John M ^a   Shiloni, Eitan ^a   Vetto, John T ^a   Seipp, Claudia A ^a   Simpson, Colleen ^a   Reichert, Cheryl M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXEPIN; HYDROXYZINE; INDOMETACIN; INTERLEUKIN 2; LYMPHOKINE; NEW DRUG; PARACETAMOL; PETHIDINE; RANITIDINE;

ADVERSE DRUG REACTION; ANEMIA; BLOOD AND HEMOPOIETIC SYSTEM; CANCER CHEMOTHERAPY; CHILL; COLON CANCER; CONFUSION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG THERAPY; DYSPNEA; EOSINOPHILIA; FEVER; FLUID RETENTION; GASTROINTESTINAL TOXICITY; GLOSSITIS; HUMAN; IMMUNOTHERAPY; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY CANCER; KILLER CELL; LARGE INTESTINE; LIVER TOXICITY; LUNG METASTASIS; LUNG TOXICITY; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALAISE; MELANOMA; METASTASIS; MOUTH; NAUSEA; NEPHROTOXICITY; NERVOUS SYSTEM; NEUROTOXICITY; NOSE CONGESTION; PRIORITY JOURNAL; PRURITUS; PSYCHOLOGICAL ASPECT; RASH; RESPIRATORY SYSTEM; SKIN TOXICITY; THERAPY; THROMBOCYTOPENIA; TUMOR REGRESSION; VOMITING; WEIGHT GAIN;

EID: 0022349817     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198512053132327     Document Type: Article

References (33)

1. Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977; 25: 323–88.
2. Rosenberg SA. Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 1984; 68: 233–55.
3. Fefer A, Einstein AB Jr, Cheever MA, Berenson JR. Models for syngeneic adoptive chemoimmunotherapy of murine leukemias. Ann NY Acad Sci 1976; 276: 573–83.
4. Kedar E, Weiss DW. The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res 1983; 38: 171–287.
5. Borberg H, Oettgen HF, Choudry K, Beattie EJ Jr. Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors. Int J Cancer 1972; 10: 539–47.
6. Cheever MA, Greenberg PD, Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 1980; 125: 711–4.
7. Fernandez-Cruz E, Halliburton B, Feldman JD. In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma. J Immunol 1979; 123: 1772–7.
8. Smith HG, Harmel RP, Hanna MG Jr, Zwilling BS, Zbar B, Rapp HJ. Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells. JNCI 1977; 58: 1315–21.
9. Berendt MJ, North RJ. T-cell-mediated suppression of anti-tumor immunity: an explanation for progressive growth of an immunogenic tumor. J Exp Med 1980; 151: 69–80.
10. Rosenberg SA. Lymphokine activated killer cells: a new approach to the immunotherapy of cancer. JNCI 1985; 75: 595–603.
11. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA. In vivo growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 1980; 125: 238–45.
12. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. In vitro growth of cytotoxic human lymphocytes. IV. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41: 4420–5.
13. Rosenberg SA, Grimm EA, Lotze MT, Mazumder A. The growth of human lymphocytes in T-cell growth factor: potential applications to tumor immunotherapy. In: Mizel SB, ed. Lymphokines. Vol. 7. New York: Academic Press, 1982:213–47.
14. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823–41.
15. Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 1984; 44: 1946–53.
16. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 1983; 157: 884–97.
17. Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 1984; 159: 495–507.
18. Mulé JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984; 225: 1487–9.
19. Mulé JJ, Shu S, Rosenberg SA. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol 1985; 135: 646–52.
20. Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 1985; 45: 3735–41.
21. Ettinghausen SE, Lipford EH, Mule JJ, Rosenberg SA. Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine activated-killer (LAK) cells. J Immunol 1985; 135: 3623–35.
22. Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Modif 1984; 3: 501–11.
23. Mazumder A, Eberlein TJ, Grimm EA, et al. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 1984; 53: 896–905.
24. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 1985; 134: 157–66.
25. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985; 135: 2865–75.
26. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007–8.
27. Rosenberg SA, Grimm EA, McGrogan M, et al. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 1984; 223: 1412–5.
28. Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol 1983; 130: 2203–8.
29. Chang AE, Hyatt CL, Rosenberg SA. Systemic administration of recombinant human interleukin-2 in mice. J Biol Response Modif 1984; 3: 561–72.
30. Gillis S, Ferm MM, Ou W, Smith KA. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 1979; 120: 2027–32.
31. Rosenberg SA, Spiess PJ, Schwarz S. In vitro growth of murine T cells. I. Production of factors necessary for T cell growth. J Immunol 1978; 121: 1946–50.
32. Matory Y, Chang AE, Spiess P, Rosenberg SA. Acute toxicity of recombinant interleukin-2 in rodents. J Biol Response Modif (in press).
33. Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161: 1169–88.